Catalog No.
PVV03201
Species reactivity
Human immunodeficiency virus 2 (HIV-2)
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant HIV-2 env/Env polyprotein/gp36 (Gln547-Tyr670).
Applications
ELISA, WB
Target
Envelope glycoprotein gp160, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, env
Concentration
1.42 mg/ml
Purification
Purified by antigen affinity column.
Accession
L8B302
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Note
For research use only.
The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1., PMID:18054388
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane., PMID:18191596
HIV-2 neutralization by intact V3-specific Fab fragments., PMID:18706111
The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients., PMID:18778482
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C., PMID:18815292
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression., PMID:18981765
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma., PMID:19019969
Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen., PMID:19084043
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination., PMID:19298995
Molecular epidemiology of HIV type 2 infections in South India., PMID:19327056
4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms., PMID:20352106
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity., PMID:20357769
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy., PMID:20844029
Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105., PMID:21175253
A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2., PMID:21232554
Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection., PMID:21283793
Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125., PMID:21541316
Frequency of human immunodeficiency virus type-2 in hiv infected patients in Maputo City, Mozambique., PMID:21849066
Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors., PMID:21902586
Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections., PMID:21993309
Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection., PMID:22031948
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes., PMID:22072758
Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein., PMID:22291921
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug., PMID:22615295
Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA., PMID:23098841
A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity., PMID:23147734
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism., PMID:23151495
Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response., PMID:24156513
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity., PMID:24352444
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals., PMID:24909946
Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family., PMID:24970741
How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses?, PMID:25445493
[Development of an antigen 'sandwich' enzyme immunoassay for the detection of antibodies against HIV-2 by using a biotinylated synthetic peptide of gp36 protein]., PMID:25482431
Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA., PMID:25514675
[Use of a synthetic peptide of HIV-2 glycoprotein 36 in antigen mixtures for the immunodiagnosis of HIV types 1 and 2]., PMID:25639906
Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency., PMID:25673728
NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles., PMID:25700718
Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its ability to detect HIV gp41 IgM antibodies., PMID:26311612
Structure of an HIV-2 gp120 in Complex with CD4., PMID:26608312
Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors., PMID:27058352
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability., PMID:27064278
eCD4-Ig Variants That More Potently Neutralize HIV-1., PMID:29593050
Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11., PMID:29618644
Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals., PMID:30715363
eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody., PMID:31068428
Selection and immune recognition of HIV-1 MPER mimotopes., PMID:32980676
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy., PMID:34821542
HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs., PMID:35563157
Cryo-EM structures of prefusion SIV envelope trimer., PMID:36344847
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates., PMID:37240423
For research use only. Not for human or drug use.
